Zimmer Biomet price target lowered to $130 from $137 at Truist

Truist lowered the firm’s price target on Zimmer Biomet to $130 from $137 and keeps a Hold rating on the shares after its Q1 results. The company has called out a few key drivers in Hips and Knee businesses that should contribute to acceleration into the second half of the year, though its guidance saw “minimal” flow-through from the modest Q1 revenue and earnings beat, the analyst tells investors in a research note.